8-K: Matinas BioPharma Secures $3.3 Million Investment and Appoints Dr. Robin L. Smith to Board

Matinas BioPharma announces a $3.3 million securities purchase agreement and the appointment of Dr. Robin L. Smith to its Board of Directors.

Summary

• Matinas BioPharma entered into a securities purchase agreement for $3.3 million with certain investors.
• The agreement involves the sale of Series C Convertible Preferred Stock and warrants to purchase common stock.
• An initial closing on February 13, 2025, generated $1.65 million in gross proceeds for 1,650 shares of preferred stock and warrants for up to 5,631,404 common shares.
• A second closing, contingent on shareholder approval, will provide an additional $1.65 million for the same amount of preferred stock and warrants.
• The preferred stock is convertible at $0.586 per share, initially convertible into 1,706 shares of common stock per preferred share.
• Warrants have an exercise price of $0.6446 per share and expire five years after shareholder approval.
• Proceeds will be used for working capital, reducing operating expenses, and exploring strategic alternatives for MAT2203.
• Dr. Robin L. Smith has been appointed to the Board of Directors.
• Herbert J. Conrad has resigned from the Board.
• The company is exploring strategic alternatives, but there is no guarantee of any agreement or transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the financing provides needed capital, the reliance on shareholder approval and the exploration of strategic alternatives introduce uncertainty. The appointment of Dr. Smith is a positive, but the resignation of Mr. Conrad is a slight negative.

Positives

• The $3.3 million investment provides additional working capital.
• Appointment of Dr. Robin L. Smith brings extensive experience to the Board.
• The company is exploring strategic alternatives for MAT2203, which could unlock value.
• The funds will be used for general corporate purposes, with a focus on reducing operating expenses and exploring strategic alternatives for MAT2203

Negatives

• The second closing is contingent on shareholder approval, which is not guaranteed.
• Herbert J. Conrad has resigned from the Board.
• There is no guarantee that the exploration of strategic alternatives will result in any agreement or transaction.

Risks

• Failure to obtain shareholder approval would prevent the second closing.
• Exploration of strategic alternatives may not result in a successful outcome.
• The company's product candidates are all in a development stage and are not available for sale or use.

Future Outlook

The company will continue to reduce operating costs while exploring strategic alternatives for MAT2203. There is no assurance that the exploration of strategic alternatives will result in any agreement or transaction, or as to the timing of any such agreement or transaction. Further, there can be no assurance that the Company will receive Stockholder Approval or that the second closing will occur.

Management Comments

• Jerome D. Jabbour, Chief Executive Officer of Matinas, stated that they are very excited to have Robin join our Board.
• Jerome D. Jabbour, Chief Executive Officer of Matinas, stated that she brings deep medical and business knowledge and experience at a critical time for our Company.
• Jerome D. Jabbour, Chief Executive Officer of Matinas, stated that I believe Dr. Smith will be an invaluable addition to our Board and can be a great contributor as we move forward.
• Jerome D. Jabbour, Chief Executive Officer of Matinas, stated that I would also like to personally thank Herb Conrad for his unwavering commitment and contributions to Matinas since we began our journey together in 2012.
• Jerome D. Jabbour, Chief Executive Officer of Matinas, stated that Herb was the first investor in the Company and provided incredible leadership throughout his years on the Board.
• Jerome D. Jabbour, Chief Executive Officer of Matinas, stated that We wish Herb all the best in his retirement.

Industry Context

The announcement reflects a common strategy for small biopharmaceutical companies to secure funding for ongoing operations and drug development. The focus on strategic alternatives for MAT2203 suggests the company is considering various options, including partnerships, licensing, or an outright sale of the asset.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical sector, such as Atea Pharmaceuticals and Cidara Therapeutics, have also pursued strategic alternatives for their lead drug candidates when facing financial constraints.
• The terms of the securities purchase agreement, including the conversion price and warrant exercise price, are within the typical range for similar financings in the micro-cap biotech space.
• The appointment of Dr. Robin L. Smith to the Board is a positive development, as she brings extensive experience in the biopharmaceutical industry and has served on multiple public company boards.
• The resignation of Herbert J. Conrad, while representing a loss of institutional knowledge, is not uncommon in companies undergoing strategic shifts.

Management Changes

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares.
• Employees: Uncertainty related to the exploration of strategic alternatives and potential cost reductions.
• Creditors: Improved financial stability due to the influx of capital.
• Customers: No immediate impact, but the strategic direction of MAT2203 could affect future product availability.

Next Steps

• The company needs to obtain shareholder approval for the issuance of shares upon conversion of the Preferred Stock and warrants.
• The company will continue to explore strategic alternatives for MAT2203.
• The company will work to reduce operating costs.

Key Dates

Keywords

securities purchase agreement, preferred stock, warrants, MAT2203, Robin L. Smith, shareholder approval, strategic alternatives, investment, biopharma, financing